Flag of the European Union EU Clinical Trials Register Help

Clinical trials for HDAC2

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44366   clinical trials with a EudraCT protocol, of which   7389   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    4 result(s) found for: HDAC2. Displaying page 1 of 1.
    EudraCT Number: 2014-003077-42 Sponsor Protocol Number: CE01-204 Start Date*: 2015-02-06
    Sponsor Name:Imperial College, London
    Full Title: A single-centre, double-blind, randomised, placebo-controlled crossover study to evaluate the effect of solithromycin on airway inflammation in male and female patients with chronic obstructive pul...
    Medical condition: Chronic Obstructive Pulmonary Disease.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002971-17 Sponsor Protocol Number: FG-2018/05 Start Date*: 2019-07-18
    Sponsor Name:Centre Georges-François Leclerc
    Full Title: Precision medicine phase II study evaluating the efficacy of a double immunotherapy by Durvalumab and Tremelimumab combined with Olaparib in patients with solid cancers and carriers of homologous r...
    Medical condition: Patients with the following solid malignancy: • Metastatic breast cancer • Metastatic prostate cancer • Metastatic lung cancer • Metastatic head and neck • Metastatic endometrial cancer • M...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064049 Lung adenocarcinoma metastatic LLT
    20.0 100000004864 10027474 Metastatic LLT
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    20.0 100000004864 10007064 Cancer of endometrium metastatic LLT
    20.0 100000004864 10036947 Prostatic cancer metastatic LLT
    20.0 100000004864 10073040 Metastatic oropharyngeal cancer LLT
    20.1 100000004864 10080007 Clear cell renal cell carcinoma metastatic LLT
    20.0 100000004864 10050076 Metastatic renal carcinoma LLT
    20.0 100000004864 10074852 Laryngeal squamous cell carcinoma metastatic LLT
    20.0 100000004864 10027478 Metastatic disease LLT
    20.0 100000004864 10046722 Urothelial carcinoma bladder stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001495-38 Sponsor Protocol Number: XYN-602 Start Date*: 2019-02-05
    Sponsor Name:Xynomic Pharmaceuticals, Inc.
    Full Title: A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
    Medical condition: Locally Advanced or Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002057-38 Sponsor Protocol Number: 64091742PCR2001 Start Date*: 2016-09-26
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
    Medical condition: mCRPC and DNA-repair anomalies
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) DK (Prematurely Ended) NL (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Dec 31 03:51:08 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA